New advances in immunotherapy for non-small cell lung cancer

American Journal of Translational Research

Haifeng Qin¹ 

[1] Department of Lung Cancer, 307th Hospital of Chinese Peoples Liberation Army, Beijing 100071, China

关键词: PD-1/PD-L1;    CTLA-4;    NSCLC;    immunotherapy;    biomarkers;   

DOI  :  

学科分类：医学（综合）

来源: e-Century Publishing Corporation

【 摘 要 】

Immunotherapy is one of the methods that can change the survival rate of patients with malignant tumors, in addition to surgery therapy, radiotherapy, chemotherapy and targeted therapy. Among various immunotherapy methods, immunoprecipitation inhibitors have been the most effective medications developed in recent years. At present, more in-depth studies have been conducted for two immune checkpoint inhibitor pathways, programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and a variety of medications for those above mentioned. The present study briefly reviews the results of clinical trials for relevant immune checkpoint inhibitors in lung cancer.

【 授权许可】

CC BY-NC